Introduction
Human immunodeficiency virus (HIV) is the causative agent of the acquired immune deficiency syndrome (AIDS) and related 570 disorders. 4 Primary HIV infection is associated with transient changes in T4/T8 lymphocyte subsets, mainly due to an increase in the number of T8+ lymphocytes.5-7 Long term seropositivity for HIV antibodies is associated with inversion ofthe T4 to T8'ratio due to decreased numbers ofT4+ cells, in some cases accompanied by an increase in T8+ cells.8-1' Clinical disease develops in a large proportion of patients with long term seropositivity for HIV antibody.'s" In both transactional and longitudinal studies a grave clinical outcome appeared to be associated with the presence of HIV antigen and the decline of HIV core antibodies in serum. ' 4'7 We report a prospective study carried out over two years in which we determined the prevalence and incidence of HIV antigenaemia among HIV antibody seropositive (n= 198) and HIV antibody seroconverted (n=58) homosexual men. The onset of clinical disease, classified according to the system used by the Centers for Disease Control,4 was studied in relation to the presence of HIV antigen in peripheral blood.
Subjects and methods
Between October 1984 and March 1986, 961 asymptomatic men living in and around Amsterdam and with at least two homosexual contacts in the preceding six months were enrolled in a prospective study of the prevalence and incidence of HIV infection and risk factors for AIDS. Epidemiological and clinical data were collected and blood sampled every three months. Of the 961 men, 723 were found to be HIV antibody seronegative and 238 HIV antibody seropositive in the first serum sample taken. The mean ages of the two groups were 34-9 (SEM 7-7) and 35-2 (6 9) years, respectively. During follow up 59 initially HIV antibody seronegative men seroconverted (end point attack rate for HIV antibody seroconversion 12-9% after 660 days). Forty HIV antibody seropositive men and one HIV antibody seroconverter failed to return for follow up at three or six months after entering the study. Sequential serum samples from the remaining 198 HIV antibody seropositive men and 58 HIV antibody seroconverters were therefore collected between October 1984 and October 1986 and tested for HIV antigen. The mean age of these two groups was 35-1 (SEM 6-5) years and mean duration of follow up (SEM 0-5) months.
HIV antigen seropositivity was defined as the presence of HIV antigen detected in three or more sequential serum samples taken over at least six months. Eleven of the 58 HIV antibody seroconverters had HIV antigen transiently in serum before seroconversion and were included in the antigen negative group.
All subjects in the study were classified according to the Centers for Disease Control system for HIV infections.4
DETECTION OF HIV ANTIBODIES AND HIV ANTIGEN
Two commercially available enzyme linked immunosorbent assays (ELISA) with purified human T cell lymphotropic virus -type TIB used as antigen (Abbott Laboratories, Chicago; Vironostika Teknika, Organon, BRITISH MEDICAL JOURNAL VOLUME 295 5 SEPTEMBER 1987 Oss, The Netherlands) were used to detect HIV antibody. Seropositivity was confirmed by immunoblotting, as described. 16 Serum samples were assayed for HIV antigen in a solid phase immuno- The solid phase immunoassay is especially sensitive for the core antigen of HIV, detecting antigen in culture supernatant of 103 cells/l of HIV infected HT-9 cells (uninfected HT-9 cell supernatant is negative). The specificity of the assay is determined in part by the rabbit antibody, which when used on Western blots of purified HIV lysate or in radioimmunoprecipitation procedures detects p55/24 (core) strongly and gpl20/41 (env) only faintly.
Purified recombinant core antigen is detectable at 50 ng/l when spiked into serum or plasma, whereas purified recombinant env antigen is detectable at roughly 500 pg/l. We quantified HIV antigen by comparing the optical densities ofthe samples with optical densities ofknown quantities ofpurified HIV lysate. With use of this antigen as a reference the detection limit of the assay was approximately 20-30 ng/l.
STATISTICS
Life table attack rates were calculated by the actuarial method." HIV antibody seroconverters were entered into intervals from the time of the first HIV antibody seropositive serum sample and HIV antigen seroconverters entered from the time of the first HIV antigen positive serum sample. Life table attack rates were compared by using the statistics of Lee and Desu."
Other statistical methods used were t tests and the X2 test.
Results Table I and figure 1 give the detailed and summarised data on HIV antigenaemia and the development of clinical disease. and 29 weeks before AIDS was diagnosed. The remaining two cases of AIDS (cases 5 and 9) were in men who initially were HIV antibody seronegative. They became HIV antigenaemic 12 and six weeks after HIV antibody seroconversion and 12 and 60 weeks before AIDS was diagnosed. In cases 1 and 2 (table II) HIV antigen remained undetectable throughout the study.
Discussion
A high proportion of subjects infected with HIV develop immunological and clinical abnormalities during long term follow up.'-'3 Previous studies have indicated that low values of HIV core antibodies in serum are associated with AIDS.'6 17 Declining levels ofantibodies to core proteins may precede the development of AIDS by months to over a year. '6 7 Subsequent studies have shown that persistent HIV antigenaemia in conjunction with declining core antibodies may be associated with progression of disease.'4'52122 This study extends our observations to the incidence of persistent HIV antigenaemia and the incidence of AIDS related complex and AIDS in relation to antigenaemia.
We found an increase in HIV antigen positivity among HIV antibody seropositive men with time resulting in an end point attack rate for HIV antigenaemia of 14-3% after about two years. antibodies indicate trapping of these antibodiesby HIV antigen in immune complexes.23 The assay that we used detects "free" antigen remaining once the amount of HIV core antibody has been exhausted. Most HIV antibody seropositive men without HIV antigenaemia remained symptom free during follow up. In addition, persistent generalised lymphadenopathy (CDG III) was as prevalent among HIV antigen negative as among HIV antigen positive men. AIDS related complex and AIDS, however, were seen more frequently among HIV antigen positive than among HIV antigen negative men. The incidence ofAIDS in our study was some 20 times higher among men who were HIV antigen positive than among those who were HIV antigen negative.
Two cases of AIDS occurred in the HIV antigen seronegative group. One patient had Burkitt's lymphoma and subsequently died, and the other had P carinii pneumonia and remained well after treatment. In sequential serum samples from both subjects circulating immune complexes containing HIV antigen were detected. 23 The duration of HIV antigenaemia before the diagnosis of AIDS varied from five to 82 weeks, ruling out any possibility of predicting the time interval between HIV antigen positivity and the development of AIDS. The same was true for the concentration of HIV antigen; high as well as low concentrations of HIV antigen were detected in those who went on to develop AIDS and in those who did not over the same period.
In conclusion our data show that the incidence of HIV antigen positivity increases with time and that the attack rate of AIDS is significantly higher among HIV antigen seropositive men than among HIV antigen seronegative men. The identification of these subgroups ofHIV antibody seropositive and symptomless men with distinguishable risks for AIDS is important; it opens the way to predict future cases of AIDS more accurately and to select subjects infected with HIV for trials ofantiviral drugs that effectively reduce the viral antigen load aiming at preventing AIDS rather than treating AIDS.
